PACAP is an Endogenous Protective Factor—Insights from PACAP-Deficient Mice

[1]  A. Tamas,et al.  Comparative Examination of Inner Ear in Wild Type and Pituitary Adenylate Cyclase Activating Polypeptide (PACAP)-Deficient Mice , 2012, Neurotoxicity Research.

[2]  A. Tamas,et al.  Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney , 2012, Neuropeptides.

[3]  J. Tajti,et al.  Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol-induced trigeminovascular activation in mice , 2012, Neurobiology of Disease.

[4]  D. Reglodi,et al.  The behavioral phenotype of pituitary adenylate-cyclase activating polypeptide-deficient mice in anxiety and depression tests is accompanied by blunted c-Fos expression in the bed nucleus of the stria terminalis, central projecting Edinger–Westphal nucleus, ventral lateral septum, and dorsal raphe n , 2012, Neuroscience.

[5]  D. Reglodi,et al.  Role of endogenous pituitary adenylate cyclase activating polypeptide (PACAP) in myelination of the rodent brain: Lessons from PACAP-deficient mice , 2011, International Journal of Developmental Neuroscience.

[6]  D. Reglodi,et al.  Pituitary adenylate cyclase-activating polypeptide plays an anti-inflammatory role in endotoxin-induced airway inflammation: In vivo study with gene-deleted mice , 2011, Peptides.

[7]  A. Tamas,et al.  Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) show increased susceptibility to in vivo renal ischemia/reperfusion injury , 2011, Neuropeptides.

[8]  H. Vaudry,et al.  Neuroprotective Effects of PACAP Against Ethanol-Induced Toxicity in the Developing Rat Cerebellum , 2011, Neurotoxicity Research.

[9]  A. Tamas,et al.  Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. , 2011, Current pharmaceutical design.

[10]  R. Hashimoto,et al.  PACAP is Implicated in the Stress Axes , 2011, Current pharmaceutical design.

[11]  G. Yadid,et al.  The role of the PACAP signaling system in depression. , 2011, Current pharmaceutical design.

[12]  S. Shioda,et al.  Role of PACAP in neural stem/progenitor cell and astrocyte--from neural development to neural repair. , 2011, Current pharmaceutical design.

[13]  J. Waschek,et al.  Immunomodulatory roles of VIP and PACAP in models of multiple sclerosis. , 2011, Current pharmaceutical design.

[14]  L. Eiden,et al.  PACAP: a master regulator of neuroendocrine stress circuits and the cellular stress response , 2011, Annals of the New York Academy of Sciences.

[15]  B. Habecker,et al.  Cardiac ischemia-reperfusion regulates sympathetic neuropeptide expression through gp130-dependent and independent mechanisms , 2011, Neuropeptides.

[16]  H. Hashimoto,et al.  Role of endogenous pituitary adenylate cyclase-activating polypeptide in adult hippocampal neurogenesis , 2011, Neuroscience.

[17]  D. Reglodi,et al.  Impaired nocifensive behaviours and mechanical hyperalgesia, but enhanced thermal allodynia in pituitary adenylate cyclase-activating polypeptide deficient mice , 2010, Neuropeptides.

[18]  F. Gallyas,et al.  Pituitary adenylate cyclase activating polypeptide in the retina: focus on the retinoprotective effects , 2010, Annals of the New York Academy of Sciences.

[19]  A. Tamas,et al.  Mice deficient in neuropeptide PACAP demonstrate increased sensitivity to in vitro kidney hypoxia. , 2010, Transplantation Proceedings.

[20]  S. Shioda,et al.  Cardioprotective effect of endogenous pituitary adenylate cyclase-activating polypeptide on Doxorubicin-induced cardiomyopathy in mice. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[21]  M. Nakata,et al.  Intra-Islet PACAP Protects Pancreatic β-Cells Against Glucotoxicity and Lipotoxicity , 2010, Journal of Molecular Neuroscience.

[22]  D. Reglodi,et al.  Pituitary Adenylate Cyclase-Activating Polypeptide Deficiency Enhances Oxazolone-Induced Allergic Contact Dermatitis in Mice , 2010, Journal of Molecular Neuroscience.

[23]  G. Toth,et al.  Protective Effect of PACAP Against Doxorubicin-Induced Cell Death in Cardiomyocyte Culture , 2010, Journal of Molecular Neuroscience.

[24]  D. Reglodi,et al.  Comparison of Intestinal Warm Ischemic Injury in PACAP Knockout and Wild-Type Mice , 2010, Journal of Molecular Neuroscience.

[25]  S. Shioda,et al.  Regulation of Oxidative Stress by Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Mediated by PACAP Receptor , 2010, Journal of Molecular Neuroscience.

[26]  D. Reglodi,et al.  Presence of Endogenous PACAP-38 Ameliorated Intestinal Cold Preservation Tissue Injury , 2010, Journal of Molecular Neuroscience.

[27]  K. Reymann,et al.  Differential regulation of CXCL12 and PACAP mRNA expression after focal and global ischemia , 2010, Neuropharmacology.

[28]  A. Tamas,et al.  Mice deficient in pituitary adenylate cyclase activating polypeptide display increased sensitivity to renal oxidative stress in vitro , 2010, Neuroscience Letters.

[29]  M. Tohyama,et al.  Increased Stathmin1 Expression in the Dentate Gyrus of Mice Causes Abnormal Axonal Arborizations , 2010, Neuroscience Research.

[30]  H. Vaudry,et al.  Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery , 2009, Pharmacological Reviews.

[31]  R. Hashimoto,et al.  Depression‐like behavior in the forced swimming test in PACAP‐deficient mice: amelioration by the atypical antipsychotic risperidone , 2009, Journal of neurochemistry.

[32]  F. Gallyas,et al.  Protection Against Chronic Hypoperfusion-Induced Retinal Neurodegeneration by PARP Inhibition via Activation of PI-3-kinase Akt Pathway and Suppression of JNK and p38 MAP Kinases , 2009, Neurotoxicity Research.

[33]  J. Waschek,et al.  Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis , 2009, Proceedings of the National Academy of Sciences.

[34]  J. Waschek,et al.  The role of endogenous PACAP in motor stimulation and conditioned place preference induced by morphine in mice , 2009, Psychopharmacology.

[35]  A. Tamas,et al.  Influence of PACAP on Oxidative Stress and Tissue Injury Following Small-Bowel Autotransplantation , 2009, Journal of Molecular Neuroscience.

[36]  Richard J. A. Wilson,et al.  Pituitary adenylate cyclase-activating polypeptide is vital for neonatal survival and the neuronal control of breathing , 2008, Respiratory Physiology & Neurobiology.

[37]  S. Onoue,et al.  Pituitary adenylate cyclase‐activating polypeptide attenuates streptozotocin‐induced apoptotic death of RIN‐m5F cells through regulation of Bcl‐2 family protein mRNA expression , 2008, The FEBS journal.

[38]  K. Nagai,et al.  Lack of light-induced elevation of renal sympathetic nerve activity and plasma corticosterone levels in PACAP-deficient mice , 2008, Neuroscience Letters.

[39]  H. Hashimoto,et al.  PACAP provides colonic protection against dextran sodium sulfate induced colitis , 2008, Journal of cellular physiology.

[40]  H. Vaudry,et al.  Inhibitory Effect of PACAP on Caspase Activity in Neuronal Apoptosis: A Better Understanding Towards Therapeutic Applications in Neurodegenerative Diseases , 2008, Journal of Molecular Neuroscience.

[41]  Takeshi Shimada,et al.  Markedly reduced white adipose tissue and increased insulin sensitivity in adcyap1-deficient mice. , 2008, Journal of pharmacological sciences.

[42]  S. Shioda,et al.  Role of PACAP in Ischemic Neural Death , 2008, Journal of Molecular Neuroscience.

[43]  A. Tamas,et al.  Effects of PACAP on Survival and Renal Morphology in Rats Subjected to Renal Ischemia/Reperfusion , 2008, Journal of Molecular Neuroscience.

[44]  F. Gallyas,et al.  PKA-Bad-14-3-3 and Akt-Bad-14-3-3 signaling pathways are involved in the protective effects of PACAP against ischemia/reperfusion-induced cardiomyocyte apoptosis , 2008, Regulatory Peptides.

[45]  V. Batuman,et al.  Renoprotection by pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases , 2008, Regulatory Peptides.

[46]  J. Waschek,et al.  Impaired nerve regeneration and enhanced neuroinflammatory response in mice lacking pituitary adenylyl cyclase activating peptide , 2008, Neuroscience.

[47]  N. Sherwood,et al.  Pituitary adenylate cyclase-activating polypeptide (PACAP) is important for embryo implantation in mice , 2008, Molecular and Cellular Endocrinology.

[48]  J. Braun,et al.  Induction of colitis and rapid development of colorectal tumors in mice deficient in the neuropeptide PACAP , 2007, International journal of cancer.

[49]  M. Endres,et al.  Pituitary adenylate cyclase‐activating polypeptide is up‐regulated in cortical pyramidal cells after focal ischemia and protects neurons from mild hypoxic/ischemic damage , 2007, Journal of neurochemistry.

[50]  A. Tamas,et al.  Pituitary adenylate cyclase activating polypeptide is protective in bilateral carotid occlusion-induced retinal lesion in rats. , 2007, General and comparative endocrinology.

[51]  H. Vaudry,et al.  Altered cerebellar development in mice lacking pituitary adenylate cyclase‐activating polypeptide , 2007, The European journal of neuroscience.

[52]  M. Brownstein,et al.  Neuroprotection by endogenous and exogenous PACAP following stroke , 2006, Regulatory Peptides.

[53]  S. Shioda,et al.  Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[54]  F. Gallyas,et al.  Pituitary adenylate cyclase activating polypeptide protects cardiomyocytes against oxidative stress-induced apoptosis , 2006, Peptides.

[55]  R. Eskay,et al.  Endogenous PACAP acts as a stress response peptide to protect cerebellar neurons from ethanol or oxidative insult , 2005, Peptides.

[56]  S. Shioda,et al.  Monoaminergic neuronal development is not affected in PACAP-gene-deficient mice , 2005, Regulatory Peptides.

[57]  H. Hashimoto,et al.  Reduced hypothermic and hypnotic responses to ethanol in PACAP-deficient mice , 2004, Regulatory Peptides.

[58]  Shijie Jin,et al.  Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells , 2004, Multiple sclerosis.

[59]  D. Reglodi,et al.  Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. , 2004, Current pharmaceutical design.

[60]  S. Matsumura,et al.  Development / Plasticity / Repair Pituitary Adenylate Cyclase-Activating Polypeptide Is Required for the Development of Spinal Sensitization and Induction of Neuropathic Pain , 2004 .

[61]  K. Nagai,et al.  Changes in light-induced phase shift of circadian rhythm in mice lacking PACAP. , 2003, Biochemical and biophysical research communications.

[62]  A. Tamas,et al.  Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent focal cerebral ischemia , 2002, Peptides.

[63]  H. Hashimoto,et al.  Defects in reproductive functions in PACAP-deficient female mice , 2002, Regulatory Peptides.

[64]  S. Shioda,et al.  Pituitary adenylate cyclase-activating polypeptide (PACAP) prevents hippocampal neurons from apoptosis by inhibiting JNK/SAPK and p38 signal transduction pathways , 2002, Regulatory Peptides.

[65]  T. Horio,et al.  The effect of pituitary adenylate cyclase activating polypeptide on cultured rat cardiocytes as a cardioprotective factor , 2002, Regulatory Peptides.

[66]  W. Young,et al.  Pituitary adenylate cyclase-activating polypeptide is a sympathoadrenal neurotransmitter involved in catecholamine regulation and glucohomeostasis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[67]  J. Miyazaki,et al.  Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP) , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[68]  F. Jirik,et al.  Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism. , 2001, Molecular endocrinology.

[69]  M. Kim,et al.  Spatial and temporal distribution of pituitary adenylate cyclase activating polypeptide in gerbil global cerebral ischemia , 2001, Neuroscience Letters.

[70]  J. Waschek,et al.  Axotomy‐induced changes in pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP receptor gene expression in the adult rat facial motor nucleus , 1999, Journal of neuroscience research.

[71]  L. Hillered,et al.  Regulation of pituitary adenylate cyclase activating polypeptide and its receptor type 1 after traumatic brain injury: comparison with brain-derived neurotrophic factor and the induction of neuronal cell death , 1999, Neuroscience.

[72]  F. Sundler,et al.  Pituitary adenylate cyclase‐activating peptide is upregulated in sensory neurons by inflammation , 1998, Neuroreport.

[73]  M. Kanje,et al.  The effects of axotomy and preganglionic denervation on the expression of pituitary adenylate cyclase activating peptide (PACAP), galanin and PACAP type 1 receptors in the rat superior cervical ganglion , 1997, Brain Research.

[74]  J. Hannibal,et al.  Expression of pituitary adenylate cyclase-activating polypeptide (PACAP) in the mesencephalic trigeminal nucleus of the rat after transsection of the masseteric nerve. , 1997, Brain research. Molecular brain research.

[75]  F. Sundler,et al.  Pituitary adenylate cyclase activating peptide expression in the rat dorsal root ganglia: Up-regulation after peripheral nerve injury , 1996, Neuroscience.

[76]  M. Culler,et al.  Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. , 1989, Biochemical and biophysical research communications.

[77]  H. Vaudry,et al.  Protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against apoptosis. , 2011, Current pharmaceutical design.

[78]  A. Tamas,et al.  Mice Deficient in Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) are More Susceptible to Retinal Ischemic Injury In Vivo , 2011, Neurotoxicity Research.

[79]  H. Hashimoto,et al.  Trophic Effects of PACAP on Pancreatic Islets: A Mini-Review , 2010, Journal of Molecular Neuroscience.

[80]  H. Hashimoto,et al.  Cerulein-Induced Acute Pancreatitis in PACAP Knockout Mice , 2010, Journal of Molecular Neuroscience.

[81]  V. Batuman,et al.  Pituitary Adenylate Cyclase-Activating Polypeptide Prevents Cisplatin-Induced Renal Failure , 2010, Journal of Molecular Neuroscience.

[82]  S. Shioda,et al.  Neuroprotective Effect of PACAP Against NMDA-Induced Retinal Damage in the Mouse , 2010, Journal of Molecular Neuroscience.

[83]  S. Shioda,et al.  Endogenous pituitary adenylate cyclase activating polypeptide is involved in suppression of edema in the ischemic brain. , 2010, Acta neurochirurgica. Supplement.

[84]  J. Hannibal.  Roles of PACAP-containing retinal ganglion cells in circadian timing. , 2006, International review of cytology.

[85]  A. Tamas,et al.  Comparative neuroprotective effects of preischemic PACAP and VIP administration in permanent occlusion of the middle cerebral artery in rats. , 2002, Neuro endocrinology letters.